Supernus Pharmaceuticals reported $725.99M in Current Liabilities for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
Ani Pharmaceuticals ANIP:US USD 81.63M 14.68M
Aurora Cannabis Inc ACB:CN CAD 185.11M 39.88M
Bristol Myers Squibb BMY:US USD 18.93B 1.98B
Canopy Growth Corp WEED:CN CAD 542.4M 137.99M
Cara Therapeutics CARA:US USD 28.19M 7.02M
Corcept Therapeutics CORT:US USD 53.07M 4.01M
Eisai 4523:JP JPY 266.54B 35.36B
Eli Lilly And LLY:US USD 15.65B 32.2M
Endo International Ordinary Shares ENDP:US USD 543.05M 638.62M
Horizon Pharma HZNP:US USD 860.61M 69.55M
JAZZ PHA JAZZ:US USD 812.95M 107.51M
Lannett LCI:US USD 110.14M 5.2M
Marinus Pharmaceuticals MRNS:US USD 21.05M 2.06M
Pacira Pharmaceuticals PCRX:US USD 131.53M 1.65M
Perrigo Ordinary Shares PRGO:US USD 1.02B 400K
Revance Therapeutics RVNC:US USD 74.73M 2.49M
Supernus Pharmaceuticals SUPN:US USD 725.99M 9.55M
Teva Pharmaceutical Industries TEVA:US USD 11.53B 538M
United Therapeutics UTHR:US USD 315.9M 15.6M
Xeris Pharmaceuticals Inc XERS:US USD 68.56M 4.01M